May 26, 2017- Interviewed by Steven E. Greer, MD
Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers are studying whether it can reduce mast cell activity in the bronchiole system to reduce symptoms of asthma. We interviewed Michael Wechsler, MD of National Jewish Health about his paper in the NEJM.